ADAG

Adagene Inc. ADR (ADAG) | Rumor.io

Adagene

ADAG

Attention (50-day avg)0%

Attention rank (50-day avg)#2,878

Bullish sentiment (50-day avg)63%

Price to earnings ratio-8.51

Market capitalization214.9M

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)7.7M

Net income (annual)-17.6M

Social

What share of all stock conversation is about ADAG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 2

Adagene Inc. (ADAG) announced updated data from a Phase 1b/2 study of muzastotug in combination with Keytruda, demonstrating improved durability of response in late-line patients with microsatellite stable colorectal cancer.
ADAG shares are trading lower after the company priced a $70 million public offering of 18.7 million ADSs at $3.75 per ADS, which may exert downward pressure on the stock price in the short term.
Early data from the Phase 1b/2 trial shows a dose-dependent response for muzastotug + Keytruda, with higher doses correlating with stronger tumor shrinkage, although confirmation is needed in larger cohorts.

Generated by AI

Sentiment

Of the messages about ADAG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	9.09% -90.91	79.78% -20.22
Bearish	—	100% new	90.91% +90.91	20.22% +20.22

Topics

Of the messages about ADAG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	30%	81.29%
Technical Analysis	—	0%	30%	11.61%
Analysts	—	0%	40%	6.45%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.65%
Macro	—	0%	0%	0%

Mar 12

$ADAG is drawing attention for progress in its immunotherapy pipeline, potentially sparking renewed momentum and short-term trading interest.
ADAG's oncology pipeline is being closely watched for potential updates and clinical developments that could trigger volatility and upside.
Traders are watching ADAG for its next breakout, with a potential oncology catalyst expected to trigger a fast mover.

Generated by AI

Community

Of the messages about ADAG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	16%	18.93%
Newcomers	—	100%	84%	81.07%

Mar 12

New investors are focusing on the upcoming trial updates that could impact the stock's momentum, with some anticipating a shift in the company's direction.
The steady trading of $ADAG is being closely watched, with some newcomers speculating that it may be a result of biotech names attracting attention.
There is a growing interest in the therapeutic potential of Adagene Inc., with some new investors highlighting the company's work in this area as a key factor in its appeal.

Generated by AI

News

Adagene Announces Finance Executive Resignation Effective September 30, 2026

Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.

3d agoThe Globe and Mail

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (“Third Arc Bio”) selected the first lead candidate under the amended strategic licensing agreement. The agreement was est

20d agoYahoo Finance

Also Discussed

Investors talking about ADAG also mention

#	Name	Attention
1	Gossamer Bio Inc.GOSS	0%+0
2	Crinetics Pharmaceuticals IncCRNX	0%new
3	Tessera Defense and Homeland Security Inc.PHGE	0%0
4	Revolution Medicines, Inc.RVMD	0.01%-0.01
5	Leverage Shares 2x Long CRML Daily ETFCRMU	0%0
6	AlloVir, Inc.ALVR	0%0
7	INZY - Inozyme Pharma, Inc.	——
8	ATHN - Athena Technology Acquisition Corp.	——
9	AIH - Aesthetic Medical International Holdings Group Limited	——
10	DZSI - DZS Inc.	——

Adagene Inc. ADR

Healthcare
Biotechnology

Adagene Inc. ADR is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company develops a platform of proprietary antibody technologies designed to improve the precision, safety, and effectiveness of biologic medicines, with current work centered on oncology and related immune-mediated diseases. Its product portfolio includes multiple investigational candidates in clinical development, reflecting a research-driven model that combines computational biology, antibody engineering, and translational science. Adagene Inc. ADR serves the healthcare and biotechnology markets by advancing differentiated therapeutic candidates aimed at complex cancers that remain difficult to treat with conventional approaches. As an ADR, the company provides investors with depositary-share exposure to its underlying business while remaining primarily identified with its biopharmaceutical operations in China.

Website

Location

Building C14

Suzhou, 215123

China

Social

What share of all stock conversation is about ADAG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 2

Adagene Inc. (ADAG) announced updated data from a Phase 1b/2 study of muzastotug in combination with Keytruda, demonstrating improved durability of response in late-line patients with microsatellite stable colorectal cancer.
ADAG shares are trading lower after the company priced a $70 million public offering of 18.7 million ADSs at $3.75 per ADS, which may exert downward pressure on the stock price in the short term.
Early data from the Phase 1b/2 trial shows a dose-dependent response for muzastotug + Keytruda, with higher doses correlating with stronger tumor shrinkage, although confirmation is needed in larger cohorts.

Generated by AI

Sentiment

Of the messages about ADAG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	9.09% -90.91	79.78% -20.22
Bearish	—	100% new	90.91% +90.91	20.22% +20.22

Topics

Of the messages about ADAG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	30%	81.29%
Technical Analysis	—	0%	30%	11.61%
Analysts	—	0%	40%	6.45%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.65%
Macro	—	0%	0%	0%

Mar 12

$ADAG is drawing attention for progress in its immunotherapy pipeline, potentially sparking renewed momentum and short-term trading interest.
ADAG's oncology pipeline is being closely watched for potential updates and clinical developments that could trigger volatility and upside.
Traders are watching ADAG for its next breakout, with a potential oncology catalyst expected to trigger a fast mover.

Generated by AI

Community

Of the messages about ADAG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	16%	18.93%
Newcomers	—	100%	84%	81.07%

Mar 12

New investors are focusing on the upcoming trial updates that could impact the stock's momentum, with some anticipating a shift in the company's direction.
The steady trading of $ADAG is being closely watched, with some newcomers speculating that it may be a result of biotech names attracting attention.
There is a growing interest in the therapeutic potential of Adagene Inc., with some new investors highlighting the company's work in this area as a key factor in its appeal.

Generated by AI

Adagene

Social

Apr 2

Mar 12

Mar 12

Adagene Announces Finance Executive Resignation Effective September 30, 2026

China approves Adagene’s IND application for ADG138 cancer drug

Adagene at H.C. Wainwright conference: higher-dose CTLA-4 push

H.C. Wainwright reiterates Adagene stock rating on milestone payments

Adagene, Third Arc Bio expand partnership with first lead selection

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Also Discussed

Adagene Inc. ADR

Company Information

Location

Adagene Announces Finance Executive Resignation Effective September 30, 2026

China approves Adagene’s IND application for ADG138 cancer drug

Adagene at H.C. Wainwright conference: higher-dose CTLA-4 push

H.C. Wainwright reiterates Adagene stock rating on milestone payments

Adagene, Third Arc Bio expand partnership with first lead selection

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Also Discussed

Social

Apr 2

Mar 12

Mar 12